NCT05885464View on ClinicalTrials.gov

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 25, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Lymphoblastic LymphomaT-Cell Lymphoblastic Leukemia/LymphomaLymphoblastic Leukemia
Interventions
BIOLOGICAL

BEAM-201

A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens

Trial Locations (10)

19104

Children's Hospital of Philadelphia, Philadelphia

37203

Sarah Cannon- TriStar Bone Marrow Transplant, Nashville

44106

Cleveland Clinic- Taussig Cancer Center, Cleveland

60637

University of Chicago, Chicago

66205

The University of Kansas Cancer Center, Fairway

78229

Methodist Hospital - Texas Transplant Institute, San Antonio

80218

Colorado Blood Cancer Institute, Denver

94304

Stanford University School of Medicine, Stanford

97239

OHSU Knight Cancer Institute Hematology Oncology, Portland

02115

Dana Farber and Boston Children's Hospital, Boston

Sponsors
All Listed Sponsors
lead

Beam Therapeutics Inc.

INDUSTRY

NCT05885464 - A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | Biotech Hunter | Biotech Hunter